YBX1 and neoplasm: We supported our findings with a combination of in vitro genetic manipulations of YB1 (CRISPR/Cas-mediated knockout) and treatment with chemotherapeutic agents, as well as in vivo mouse models of TNBC to show that the loss of YB1 expression inhibits its oncogenic activity both in vitro (colony formation) and in vivo (inhibition of tumor growth and metastasis) in TNBC cell lines of both CA and AA origin.